The global breast cancer therapeutics market is expected to grow at an impressive CAGR in the forecast period, 2023-2027. The growing geriatric population who are more susceptible to several chronic illnesses such as cancer is propelling the growth of the global breast cancer therapeutics market.

The rising incidences and high prevalence rate of breast cancer across the world are expected to augment the global breast cancer therapeutics market. With this, extensive investment in research and development activities and technological advancements in cancer biology and pharmacology promote breast cancer therapeutics. Continuous upgrades help increase understanding of breast cancer at the molecular level, and the introduction of novel solutions has assisted in lowering the breast cancer mortality rate over the past few years. Newly developed therapeutics efficiently slow down the growth and proliferation of cancerous cells, which is projected to boost the global breast cancer therapeutics market in the upcoming years.

Rise in Cases of Breast Cancer Augments the Market Growth

The growing prevalence of breast cancer across the globe and the escalating demand for effective treatment for a large number of patients are expected to stimulate the growth of the breast cancer therapeutics market. Breast cancer is considered one of the prevalent forms of cancer across the world, and enhanced diagnostic solutions are expected to propel market growth. The escalating demand for preventive care and early treatment due to its numerous benefits led individuals to go for diagnostic procedures, further driving the global breast cancer therapeutics market growth.

Launch of Awareness Programs by Government Stimulates the Market Growth

The breast cancer screening initiatives by government bodies and supportive programs introduced by public organizations are anticipated to stimulate the growth of the global breast cancer therapeutics market. According to the WHO report, early detection of breast cancer assists in minimizing the breast cancer mortality rate and accelerates the survival rate among patients who have breast cancer. Numerous government bodies across the globe encourage people to undergo breast cancer screening, especially women aged 50 and over. The screening initiatives and awareness programs are projected to propel the utilization of drugs for the effective treatment of breast cancer, driving the global breast cancer therapeutics market growth over the forecast period.

Escalating Demand for Targeted Therapy Supports the Market Growth

Treatment for breast cancer across the globe is a challenging task for any medical oncologist. The availability of treatment and choice varies from patient to patient. Targeted therapy is preferred over any other therapy as it precisely targets the breast cancer cells without damaging the surrounding healthy cells. The targeted therapy aids medical professionals in overcoming numerous limitations posed by traditional treatments. Targeted therapy also helps oncologists focus more on preventive care than reactive care. This therapy enhances the treatment efficiency in patients diagnosed with advanced stages of breast cancer, which further contributes to the growth of the global breast cancer therapeutics market.


 

Click here to download the sample

Market Segmentation

The global breast cancer therapeutics market is segmented into type, end users, and regional distribution. Based on the type, the market is divided into chemotherapy, hormone therapy, immunotherapies, targeted therapy, and others. The chemotherapy drugs are further divided into anthracyclines, taxanes, antimetabolites, others and hormone therapy are divided into selective estrogen receptor modulators, aromatase inhibitors, and others. Also, the targeted therapy is divided into monoclonal antibodies, tyrosine kinase inhibitor, herceptin, and others. Based on the end users, the market is divided into hospitals, specialty clinics, ambulatory surgical centers, and others. The market analysis also studies the regional segmentation, divided among North American region, Asia-Pacific region, European region, South American region, and Middle East & African region.

Market Players

Novartis AG, Pfizer Inc., Eli Lilly & Company, Merck Co. & Inc., GlaxoSmithKline, Plc., AstraZeneca Plc., Bristol-Myers Squibb Company, Halozyme Inc., Eisai Co., Ltd., Fresenius Kabi AG are the leading market players contributing the growth of the global breast cancer therapeutics market.

Attribute

Details

Base Year

2021

Historic Data

2017 – 2020

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

·         Therapy

·         End User

Regional scope

North America; Asia Pacific; Europe; South America; Middle East & Africa

Country scope

United States; Canada; Mexico; China; India; Japan; South Korea; Australia; Singapore; Malaysia; Germany; United Kingdom; France; Italy; Spain; Poland; Denmark; Brazil; Argentina; Colombia; Poland; Denmark; Saudi Arabia; South Africa; UAE; Iraq; Turkey

Key companies profiled

Novartis AG, Pfizer Inc., Eli Lilly & Company, Merck Co. & Inc., GlaxoSmithKline, Plc., AstraZeneca Plc., Bristol-Myers Squibb Company, Halozyme Inc., Eisai Co., Ltd., Fresenius Kabi AG

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Report Scope:

In this report, global breast cancer therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Breast Cancer Diagnostics Market, By Therapy:
    • Chemotherapy
      • Anthracyclines
      • Taxanes
      • Antimetabolites
      • Others
    • Hormone Therapy
      • Selective Estrogen Receptor Modulators
      • Aromatase Inhibitors
      • Others
    • Immunotherapies
    • Targeted Therapy
      • Monoclonal Antibodies
      • Tyrosine Kinase Inhibitor
      • Herceptin
      • Others
    • Others
  • Breast Cancer Diagnostics Market, By End-User:
    • Hospitals
    • Specialty Clinics
    • Ambulatory Surgical Centers
    • Others
  • Breast Cancer Diagnostics, By Region:
    • North America
      • United States
      • Canada
      • Mexico
    • Asia-Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa

§  Saudi Arabia

§  South Africa

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global breast cancer therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global breast cancer therapeutics market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com  

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com

1.    Product Therapy Overview

2.    Research Methodology

3.    Impact of COVID-19 on Global Breast Cancer Therapeutics Market

4.    Voice of Customer

5.    Executive Summary

6.    Global Breast Cancer Therapeutics Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)

6.2.1.1.         Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)

6.2.1.2.         Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)

6.2.1.3.         Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)

6.2.2.     By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

6.2.3.     By Company (2021)

6.2.4.     By Region

6.3.  Product Market Map

7.    North America Breast Cancer Therapeutics Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)

7.2.1.1.         Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)

7.2.1.2.         Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)

7.2.1.3.         Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)

7.2.2.     By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

7.2.3.     By Country

7.3.  North America: Country Analysis

7.3.1.     United States Breast Cancer Therapeutics Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Therapy

7.3.1.2.2.             By End User

7.3.2.     Mexico Breast Cancer Therapeutics Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Therapy

7.3.2.2.2.             By End User

7.3.3.     Canada Breast Cancer Therapeutics Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Therapy

7.3.3.2.2.             By End User

8.    Europe Breast Cancer Therapeutics Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)

8.2.1.1.         Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)

8.2.1.2.         Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)

8.2.1.3.         Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)

8.2.2.     By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

8.2.3.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France Breast Cancer Therapeutics Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Therapy

8.3.1.2.2.             By End User

8.3.2.     Germany Breast Cancer Therapeutics Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Therapy

8.3.2.2.2.             By End User

8.3.3.     United Kingdom Breast Cancer Therapeutics Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Therapy

8.3.3.2.2.             By End User

8.3.4.     Italy Breast Cancer Therapeutics Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Therapy

8.3.4.2.2.             By End User

8.3.5.     Spain Breast Cancer Therapeutics Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Therapy

8.3.5.2.2.             By End User

9.    Asia-Pacific Breast Cancer Therapeutics Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)

9.2.1.1.         Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)

9.2.1.2.         Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)

9.2.1.3.         Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)

9.2.2.     By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

9.2.3.     By Country

9.3.  Asia-Pacific: Country Analysis

9.3.1.     China Breast Cancer Therapeutics Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Therapy

9.3.1.2.2.             By End User

9.3.2.     India Breast Cancer Therapeutics Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Therapy

9.3.2.2.2.             By End User

9.3.3.     Japan Breast Cancer Therapeutics Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Therapy

9.3.3.2.2.             By End User

9.3.4.     South Korea Breast Cancer Therapeutics Market Outlook

9.3.4.1.         Market Size & Forecast

9.3.4.1.1.             By Value

9.3.4.2.         Market Share & Forecast

9.3.4.2.1.             By Therapy

9.3.4.2.2.             By End User

9.3.5.     Australia Breast Cancer Therapeutics Market Outlook

9.3.5.1.         Market Size & Forecast

9.3.5.1.1.             By Value

9.3.5.2.         Market Share & Forecast

9.3.5.2.1.             By Therapy

9.3.5.2.2.             By End User

10.  South America Breast Cancer Therapeutics Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)

10.2.1.1.      Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)

10.2.1.2.      Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)

10.2.1.3.      Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)

10.2.2.  By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

10.2.3.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Breast Cancer Therapeutics Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Therapy

10.3.1.2.2.           By End User

10.3.2.  Argentina Breast Cancer Therapeutics Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Therapy

10.3.2.2.2.           By End User

10.3.3.  Colombia Breast Cancer Therapeutics Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Therapy

10.3.3.2.2.           By End User

11.  Middle East and Africa Breast Cancer Therapeutics Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)

11.2.1.1.      Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)

11.2.1.2.      Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)

11.2.1.3.      Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)

11.2.2.  By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

11.2.3.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa Breast Cancer Therapeutics Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Therapy

11.3.1.2.2.           By End User

11.3.2.  Saudi Arabia Breast Cancer Therapeutics Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Therapy

11.3.2.2.2.           By End User

11.3.3.  UAE Breast Cancer Therapeutics Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Therapy

11.3.3.2.2.           By End User

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

14.  Competitive Landscape

14.1.              Novartis AG

14.2.              Pfizer Inc.

14.3.              Eli Lilly & Company

14.4.              Merck Co. & Inc.

14.5.              GlaxoSmithKline, Plc.

14.6.              AstraZeneca Plc.

14.7.              Bristol-Myers Squibb Company

14.8.              Halozyme Inc.

14.9.              Eisai Co., Ltd.

14.10.            Fresenius Kabi AG

15. Strategic Recommendations

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com